Hot search
FibroScan® Fatty Liver Solutions Solutions for People at High Risk of Liver Cancer
English
Chinese
French
Assessment
Assessment
Make an Appointment for Screening
aMAP Score
FAST Score

FibroScan exclusive/pioneering indicator

CAP [dB/m]:
E [kPa]:
* Note: This report is for clinical reference only and should not be considered a final diagnostic result.
Submit results
The submitted content does not meet the standards. Please re-enter or contact us
CAP [dB/m]:

SD

5

Average score

260

CAP score analysis

CAP represents the attenuation of ultrasound signals within the liver and reflects the liver’s fat content. It is used to assess the severity of fatty liver disease.

E [kPa]:

IQR

0.6

IQR/Median score

15%

Median score

3.9

E-score analysis

Liver stiffness measurements range from 1.5 kPa to 75 kPa and can indicate the degree of liver fibrosis to some extent. Fibrosis is the liver’s self-repair process following injury; prolonged liver damage can eventually lead to liver cirrhosis.

* Note: This report is for clinical reference only and should not be considered a final diagnostic result.
FibroScan exclusive/pioneering indicator
Scan
Fibroscanmini-program
To obtain more calculation tools

FibroScan® examination can provide a basis for
treatment decisions in various liver diseases

Two core technologies of FibroScan®
Vibration-Controlled Transient Elastography (VCTE) technology
Vibration-Controlled Transient Elastography (VCTE) technology
Controlled Attenuation Parameter (CAP) technology
Controlled Attenuation Parameter (CAP) technology

VCTE™ liver stiffness measurement（LSM）assesses liver fibrosis

CAP™ assesses liver steatosis

VCTE™ splenic stiffness measurement（SSM）assesses portal hypertension and monitors gastroesophageal varices

FibroScan® examination can provide a basis fortreatment decisions in various liver diseases
Obtain the best assessment

Obtain the best assessment

Fast™
Fast™

Purpose

Clinical trial screening and identification of high-risk patients with metabolic dysfunction-associated steatohepatitis (MASH)

Agile 3+
Agile 3+

Purpose

Identify patients with MAFLD with progressive fibrosis and predicting complication risk

Agile 4
Agile 4

Purpose

Identify patients with MAFLD and liver cirrhosis requiring screening for HCC

Liver cancer risk assessment patent score:

aMAP score (age-male-AIBi-platelets score): A liver cancer risk assessment tool designed for various chronic liver diseases and families of liver diseases.

Scoring breakdown:
Clinical parameters
Age Gender
Blood test parameters
Albumin Total bilirubin Platelet count

The Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2024 Edition) issued by the National Health Commission recommend the use of the aMAP score for early screening and diagnosis of liver cancer, aiding in the rapid identification of high-risk populations.

< 50 Low risk
50-60 Medium risk
> 60 High risk

Why undergo liver cancer risk assessment (aMAP)?

01
High incidence and mortality of liver cancer patients in China: In 2022, the number of new liver cancer cases in China reached 367,700, ranking 5th among all cancer types; the number of deaths was 316,500, ranking 2nd.
02
Low 5-year survival rate for liver cancer in China: The 5-year survival rate for liver cancer is only 11.7%–14.1%. Improving early diagnosis rates is one of the key measures to increase the 5-year survival rate.
03
Rapid and convenient identification of high-risk populations is a prerequisite for large-scale liver cancer screening, and stratified risk assessment of the population is the basis for formulating different liver cancer screening strategies.
04
Screening and monitoring of high-risk populations for liver cancer facilitate early detection, diagnosis, and treatment, while significantly reducing the risk of patient mortality. High-risk individuals should undergo screening at least once every six months.

Fast Calculator

Identify high-risk MASH in patients with MAFLD

aMAP Calculator

Assess liver cancer risk of multiple chronic liver diseases

Fibroscan
Make an appointment for screening

Fatty liver
Solutions

People at high risk of liver cancer
Solutions